Cambridge Investment Research Advisors, Inc. Kymera Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 9,025 shares of KYMR stock, worth $554,496. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,025
Previous 9,014
0.12%
Holding current value
$554,496
Previous $247,000
59.51%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding KYMR
# of Institutions
222Shares Held
72.3MCall Options Held
178KPut Options Held
64.6K-
Price T Rowe Associates Inc Baltimore, MD6.86MShares$421 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6.65MShares$409 Million2.94% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.56MShares$403 Million5.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$345 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$338 Million9.44% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $3.36B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...